Literature DB >> 15769099

Pyrazolyl derivatives as bifunctional chelators for labeling tumor-seeking peptides with the fac-[M(CO)3]+ moiety (M = 99mTc, Re): synthesis, characterization, and biological behavior.

Susana Alves1, António Paulo, João D G Correia, Lurdes Gano, Charles J Smith, Timothy J Hoffman, Isabel Santos.   

Abstract

Radiolabeling of biologically active molecules with the [(99m)Tc(CO)(3)](+) unit has been of primary interest in recent years. With this in mind, we herein report symmetric (L(1)) and asymmetric (L(2)-L(5)) pyrazolyl-containing chelators that have been evaluated in radiochemical reactions with the synthon [(99m)Tc(H(2)O)(3)(CO)(3)](+) (1a). These reactions yielded the radioactive building blocks [(99m)Tc(CO)(3)(k(3)-L)](+) (L = L(1)-L(5), 2a-6a), which were identified by RP-HPLC. The corresponding Re surrogates (2-6) allowed for macroscopic identification of the radiochemical conjugates. Complexes 2a-6a, with log P(o/w) values ranging from -2.35 to 0.87, were obtained in yields of > or =90% using ligand concentrations in the 10(-5-)10(-4) M range. Challenge studies with cysteine and histidine revealed high stability for all of these radioactive complexes, and biodistribution studies in mice indicated a fast rate of blood clearance and high rate of total radioactivity excretion, occurring primarily through the renal-urinary pathway. Based on the framework of the asymmetric chelators, the novel bifunctional ligands 3,5-Me(2)-pz(CH(2))(2)N((CH(2))(3)COOH)(CH(2))(2)NH(2) (L(6)) and pz(CH(2))(2)N((CH(2))(3)COOH)(CH(2))(2)NH(2) (L(7)) have been synthesized and their coordination chemistry toward (NEt(4))(2)[ReBr(3)(CO)(3)] (1) has been explored. The resulting complexes, fac-[Re(CO)(3)(k(3)-L)]Br (L(6)(7), L(7)(8)), contain tridentate ancillary ligands that are coordinated to the metal center through the pyrazolyl and amine nitrogen atoms, as observed for the other related building blocks. L(6) and L(7) were coupled to a glycylglycine ethyl ester dipeptide, and the resulting functionalized ligands were used to prepare the model complexes fac-[Re(CO)(3)(kappa(3)-3,5-Me(2)-pz(CH(2))(2)N(glygly)(CH(2))(2)NH(2))](+) (9/9a) and fac-[Re(CO)(3)(kappa(3)-pz(CH(2))(2)N(CH(2))(3)(glygly)(CH(2))(2)NH(2))](+) (10/10a) (M = Re, (99m)Tc). These small conjugates have been fully characterized and are reported herein. On the basis of the in vitro/in vivo behavior of the model complexes (2a-6a, 9a, 10a), we chose to evaluate the in vitro/in vivo biological behavior of a new tumor-seeking Bombesin pyrazolyl conjugate, [(L(6))-G-G-G-Q-W-A-V-G-H-L-M-NH(2)], that has been labeled with the [(99m)Tc(CO)(3)](+) metal fragment. Stability, in vitro cell binding assays, and pharmacokinetics studies in normal mice are reported herein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769099     DOI: 10.1021/bc0497968

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  10 in total

1.  Evaluation of novel 99mTc(I)-labeled homobivalent α-melanocyte-stimulating hormone analogs for melanocortin-1 receptor targeting.

Authors:  Maurício Morais; Paula D Raposinho; Maria Cristina Oliveira; João D G Correia; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2012-04       Impact factor: 3.358

Review 2.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells.

Authors:  Arijit Ghosh; Natarajan Raju; Michael Tweedle; Krishan Kumar
Journal:  Cancer Biother Radiopharm       Date:  2017-02       Impact factor: 3.099

4.  Nuclear targeting with cell-specific multifunctional tricarbonyl M(I) (M is Re, (99m)Tc) complexes: synthesis, characterization, and cell studies.

Authors:  Teresa Esteves; Fernanda Marques; António Paulo; José Rino; Prasant Nanda; C Jeffrey Smith; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2011-06-25       Impact factor: 3.358

5.  Design and synthesis of a bombesin peptide-conjugated tripodal phosphino dithioether ligand topology for the stabilization of the fac-[M(CO)3]+ core (M=(99 m)Tc or Re).

Authors:  Raghuraman Kannan; Nagavarakishore Pillarsetty; Hariprasad Gali; Timothy J Hoffman; Charles L Barnes; Silvia S Jurisson; Charles J Smith; Wynn A Volkert
Journal:  Inorg Chem       Date:  2011-05-18       Impact factor: 5.165

Review 6.  Metal Peptide Conjugates in Cell and Tissue Imaging and Biosensing.

Authors:  Karmel S Gkika; David Cullinane; Tia E Keyes
Journal:  Top Curr Chem (Cham)       Date:  2022-06-15

7.  Synthesis, characterization, and evaluation of a novel 99mTc(CO)3 pyrazolyl conjugate of a peptide nucleic acid sequence.

Authors:  Catarina Xavier; Clelia Giannini; Sergio Dall'Angelo; Lurdes Gano; Stefano Maiorana; Roger Alberto; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2008-09-06       Impact factor: 3.358

8.  Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties.

Authors:  Paula D Raposinho; Catarina Xavier; João D G Correia; Soraia Falcão; Paula Gomes; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2008-01-08       Impact factor: 3.358

9.  A new bisphosphonate-containing (99m)Tc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation.

Authors:  Elisa Palma; Bruno L Oliveira; João D G Correia; Lurdes Gano; Leonor Maria; Isabel C Santos; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2007-03-02       Impact factor: 3.862

10.  Synthesis and Biological Evaluation of 99mTc(I) Tricarbonyl Complexes Dual-Targeted at Tumoral Mitochondria.

Authors:  Diogo Figueiredo; Célia Fernandes; Francisco Silva; Elisa Palma; Paula Raposinho; Ana Belchior; Pedro Vaz; António Paulo
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.